Physician profile
Gary R Highfill
NPI 1073693909
$1,568.50
in general payments reported to CMS, 2019-2025
22 companies · $65.25 in 2025
The $65.25 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $217 · 2021: $77.91 · 2022: $794 · 2023: $158 · 2024: $121 · 2025: $65.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $344.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $320.38 | 2022 | |
| Stryker Corporation | $260.05 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $171.92 | 2021-2023 | Dupixent |
| Acclarent, INC | $133.47 | 2019-2024 | Acclarent Aera, Acclarent Navwire |
| Intersect Ent, INC. | $131.32 | 2019-2020 | |
| Genzyme Corporation | $83.04 | 2022-2023 | |
| Kaleo, INC. | $74.58 | 2019-2022 | |
| Integra Lifesciences Corporation | $49.33 | 2025 | Relieva Spinplus Nav, Inspira Air, Acclarent Aera |
| Abbott Laboratories | $41.62 | 2022-2023 | Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $40.38 | 2022-2023 | |
| Ascendis Pharma Endocrinology INC | $36.65 | 2023 | |
| Xeris Pharmaceuticals, INC. | $32.21 | 2022-2023 | Gvoke Hypopen |
| Ambu INC. | $27.06 | 2022 | |
| Tandem Diabetes Care, INC. | $24.46 | 2022 | |
| Kyowa Kirin, INC. | $22.57 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $20.37 | 2022 | |
| Alk-Abello, INC | $19.02 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.38 | 2019 | |
| Glaxosmithkline, LLC. | $17.16 | 2022 | |
| Genentech USA, INC. | $15.92 | 2025 | Xolair |
| Scynexis, INC. | $15.52 | 2022 | |
| Currax Pharmaceuticals LLC | $14.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Highfill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.